10-QPeriod: Q3 FY2022

DEXCOM INC Quarterly Report for Q3 Ended Sep 30, 2022

Filed October 27, 2022For Securities:DXCM

Summary

DexCom, Inc. reported strong financial results for the third quarter and the first nine months of 2022, demonstrating robust revenue growth and improved profitability. For the three months ended September 30, 2022, revenue increased by 18% year-over-year to $769.6 million, driven by increased sales volume of disposable sensors. Net income also saw a healthy increase of 16% to $101.2 million. The company's operational efficiency is evident in its gross profit, which grew 11% to $494.2 million, though the gross profit margin decreased slightly year-over-year due to price, product, and channel mix changes. Operating expenses were managed effectively, with a notable decrease in research and development expenses, contributing to a 25% increase in operating income to $147.5 million. The balance sheet remains solid, with a significant cash and short-term marketable securities balance of $2.37 billion as of September 30, 2022. Overall, DexCom continues to exhibit strong growth and operational performance, indicating a positive trajectory. Investors should note the strategic focus on product innovation and market expansion, including the development of its next-generation G7 system, as key drivers for future growth. The company's proactive approach to managing its capital resources and debt obligations, coupled with ongoing investments in R&D, positions it well within the growing diabetes management market.

Financial Highlights

53 data points
Beta

Revenue

$769.60M

64.2% Gross Margin

Net Income

$101.20M

13.1% Net Margin

EPS (Diluted)

$0.24

Total Assets

$4.90B

Cash & Equivalents

$699.10M

Free Cash Flow

$185.00M

Financial Statements
Beta
Revenue$769.60M
Cost of Revenue$275.40M
Gross Profit$494.20M
R&D Expenses$110.30M
SG&A Expenses$234.60M
Operating Expenses$346.70M
Operating Income$147.50M
Interest Expense$3.70M
Net Income$101.20M
EPS (Basic)$0.26
EPS (Diluted)$0.24
Shares Outstanding (Basic)389.80M
Shares Outstanding (Diluted)425.80M

Key Highlights

  • 1Revenue for the third quarter of 2022 increased by 18% to $769.6 million compared to the same period in 2021.
  • 2Net income for the third quarter of 2022 increased by 16% to $101.2 million compared to the same period in 2021.
  • 3Operating income for the third quarter of 2022 increased by 25% to $147.5 million compared to the same period in 2021.
  • 4Gross profit for the third quarter of 2022 increased by 11% to $494.2 million compared to the same period in 2021, though gross profit margin decreased slightly.
  • 5Research and development expenses decreased by 14% in the third quarter of 2022 compared to the same period in 2021.
  • 6The company ended the third quarter of 2022 with $2.37 billion in cash, cash equivalents, and short-term marketable securities.
  • 7Dexcom announced a share repurchase program of up to $700.0 million of its outstanding common stock.

Frequently Asked Questions

Revenue growth of 18% was primarily driven by an increase in the sales volume of disposable sensors, reflecting the continued expansion of Dexcom's worldwide customer base. This growth was partially offset by shifts in product and channel mix and pricing strategies, as well as the impact of foreign currency fluctuations on revenue.

Dexcom effectively managed its operating expenses. Research and development expenses decreased by 14% in the third quarter of 2022 compared to the prior year, mainly due to lower third-party and consulting fees for software development and reduced clinical trial costs. Selling, general, and administrative expenses increased primarily due to higher compensation costs and increased advertising and marketing spend.

As of September 30, 2022, Dexcom maintained a strong liquidity position with $2.37 billion in cash, cash equivalents, and short-term marketable securities. The company generated positive cash flow from operations and has access to a $200 million revolving credit facility. Dexcom also authorized a $700 million share repurchase program, demonstrating its commitment to returning value to shareholders while maintaining financial flexibility for growth initiatives.

Key risks and challenges include ongoing pricing pressures from third-party payors, potential reimbursement hurdles, intense competition within the CGM market, the need to scale manufacturing efficiently, the successful development and commercialization of new products like the G7 system, and potential supply chain disruptions. The company also faces risks related to regulatory compliance, intellectual property protection, and the broader economic environment.